` KZR (Kezar Life Sciences Inc) vs S&P 500 Comparison - Alpha Spread

KZR
vs
S&P 500

Over the past 12 months, KZR has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +18% growth.

Stocks Performance
KZR vs S&P 500

Loading
KZR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
KZR vs S&P 500

Loading
KZR
S&P 500
Difference
www.alphaspread.com

Performance By Year
KZR vs S&P 500

Loading
KZR
S&P 500
Add Stock

Competitors Performance
Kezar Life Sciences Inc vs Peers

S&P 500
KZR
ABBV
CYTH
AMGN
GILD
Add Stock

Kezar Life Sciences Inc
Glance View

Market Cap
31.4m USD
Industry
Biotechnology

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. The company is headquartered in South San Francisco, California and currently employs 56 full-time employees. The company went IPO on 2018-06-21. The firm's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. The firm has two drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. The Company’s principal operations are in South San Francisco, California.

KZR Intrinsic Value
13.92 USD
Undervaluation 69%
Intrinsic Value
Price
Back to Top